Lita Nelsen is the former long-time director of the Technology Licensing Office at the Massachusetts Institute of Technology. Her talk with Nature Biotechnology covers her father’s life designing television antennas, what drove her to the chemical engineering program at MIT, and the ingredients required to create an entrepreneurial environment on campus (and beyond). See acast.com/privacy for privacy and opt-out information.

First Rounders

Lita Nelsen

Stan Crooke is born ⬩ A tenuous existence ⬩ Life with his mother ⬩ The Tech Corner ⬩ Arsenal Tech High School ⬩ Nancy ⬩ Hoodlum ways ⬩ Off to Purdue See acast.com/privacy for privacy and opt-out information.

Hope Lies in Dreams Chapter 1

Anthony Atala is the director of the Institute for Regenerative Medicine at Wake Forest University. He is also a co-founder of Precise Bio. His conversation with Nature Biotechnology covers implanting the first tissue-engineered bladder into a patient, Wake Forest’s plans for fostering entrepreneurship, and how he was coerced into a research career by a mentor. See acast.com/privacy for privacy and opt-out information.

Anthony Atala

Nancy Simonian is president and CEO of Syros Pharmaceuticals. Her conversation with Nature Biotechnology covers going against the advice of her mentor to take a job at Biogen; the long, winding path to approval for the multiple myeloma drug Velcade; and assisting her father in the operating room as a girl. See acast.com/privacy for privacy and opt-out information.

Nancy Simonian

Carl June is a co-founder of Tmunity Therapeutics, and a professor in immunotherapy at the University of Pennsylvania, where he also runs the June Lab. His conversation with Nature Biotechnology includes how a boyhood fractured arm led him to his first scientific experiment, his years of service with the Navy, and his groundbreaking work with CAR T-cells. See acast.com/privacy for privacy and opt-out information.

Carl June

Craig Mello is co-founder of Atalanta Therapeutics and a professor at the University of Massachusetts Medical School, where he runs the Mello Lab. He is also a Nobel Laureate. His conversation with Nature Biotechnology covers the lure of conspiracy theorists, the state of RNA therapeutics, and getting that call from the Nobel committee.  See acast.com/privacy for privacy and opt-out information.

Craig Mello

Neil Kumar is a co-founder and CEO of BridgeBio Pharma. He discussed with Nature Biotechnology his youth in the Midwest, the founding principles behind BridgeBio, and understanding where your strengths lie. See acast.com/privacy for privacy and opt-out information.

Neil Kumar

Grace Colón is president and CEO of InCarda Therapeutics. Her conversation with Nature Biotechnology covers growing up in San Juan, Puerto Rico; her love of musical theater; and how grad school at MIT guided her toward a career in entrepreneurship.   See acast.com/privacy for privacy and opt-out information.

Grace Colón

Tillman Gerngross is the CEO and co-founder of Adimab, and a professor of bioengineering at Dartmouth College. His conversation with Nature Biotechnology covers his years at GlycoFi, the nature of problem solving in entrepreneurship, and Adimab’s paper last year challenging the work of MIT researcher Ram Sasisekharan.  See acast.com/privacy for privacy and opt-out information.

Tillman Gerngross

Noubar Afeyan is the founder and CEO of Flagship Pioneering. His conversation with Nature Biotechnology covers his family fleeing the Lebanese Civil War when he was a boy, how a chance encounter at a scientific meeting opened his mind to entrepreneurism, and why immigrants (and entrepreneurs) benefit from having a “paranoid optimist” mindset.  See acast.com/privacy for privacy and opt-out information.

Noubar Afeyan

Katrine Bosley is former CEO of Editas Medicines and Avila Therapeutics. She discusses growing up in Ohio, her first job in biotech (as an administrative assistant) and why her five years at CRISPR company Editas felt more like 1,000. This episode is part of Nature Biotechnology's focus issue on translating the CRISPR technology. See acast.com/privacy for privacy and opt-out information.

Katrine Bosley

Ted Love is the president and CEO of Global Blood Therapeutics. In his conversation with Nature Biotechnology, he discusses why his time at Haverford College was transformative, why he views Global Blood Therapeutics as a social justice company, and what might be gained from the “racial catharsis” happening in America after the police killing of George Floyd. See acast.com/privacy for privacy and opt-out information.

Ted Love

Alexis Borisy is CEO and Chairman of EQRx, and a long-time biotech builder with Third Rock Ventures. His conversation with Nature Biotechnology covers growing up as a “faculty brat” in Wisconsin, dropping out of his PhD program at Harvard and why, even as an investor, biotech cannot be all about the money.  See acast.com/privacy for privacy and opt-out information.

Alexis Borisy

A conversation with Jeremy Levin, chairman of the Biotechnology Innovation Organization and CEO of Ovid Therapeutics, about industry versus government responses to covid19, the split within biotech on how to address charges of high prices, and why the biopharma industry is so disliked.  See acast.com/privacy for privacy and opt-out information.

Bonus: Jeremy Levin

Bassil Dahiyat is co-founder, president and CEO of Xencor. His conversation with Nature Biotechnology covers his parents emigrating from Jordan, how Xencor has survived (and changed) over the past 22 years, and when it’s necessary for a CEO to speak out. See acast.com/privacy for privacy and opt-out information.

Bassil Dahiyat

Nature Biotechnology's First Rounders podcast is a series of conversations with founders, financers and developers from biotech's past, present and future.

hubhopper

First Rounders

hubhopper